Chapter 54: Anemia Drugs

Anemias are categorized into four distinct pathophysiological groups: cytoplasmic maturation defects including iron-deficiency anemia and thalassemia, nuclear maturation defects such as pernicious anemia from vitamin B12 insufficiency and folic acid-related anemia, and hemolytic anemias resulting from either intrinsic cellular abnormalities like sickle cell disease and glucose-6-phosphatase deficiency or extrinsic destructive forces including drug-induced immune responses and mechanical device damage. Erythropoiesis-stimulating agents such as epoetin alfa and darbepoetin address anemia in chronic kidney disease, cancer therapy, and HIV management, though their use requires vigilance regarding serious adverse events including hypertension elevation, stroke risk, thrombotic complications, and potential tumor acceleration. Iron supplementation encompasses both oral preparations like ferrous sulfate and ferric gluconate formulations and parenteral options including iron dextran and iron sucrose, with iron serving as an essential hemoglobin and myoglobin component; clinical concerns include gastrointestinal irritation, constipation, black discoloration of stool, and potentially fatal pediatric overdose requiring chelation intervention with deferoxamine. Drug interactions with ascorbic acid, antacids, and specific antibiotics necessitate careful medication timing and administration sequencing. Folic acid supplementation supports DNA synthesis and erythrocyte development while preventing neural tube defects during pregnancy and treating megaloblastic anemia, though practitioners must exclude pernicious anemia before initiation to prevent masking of neurological manifestations. Cyanocobalamin represents the primary therapeutic approach for pernicious anemia, typically administered through deep intramuscular injection. Comprehensive nursing assessment includes detailed patient history, identification of anemia manifestations such as fatigue and nail changes, baseline laboratory evaluation encompassing red cell counts and vitamin levels, patient education regarding dietary iron sources and medication adherence, and recognition of treatment-related adverse effects for optimal therapeutic outcomes.